Triglycerides are the principal form in which excess fatty acids are stored in adipose tissue and are also an important circulating energy source. A triglyceride molecule consists of glycerol esterified with three fatty acids. After meals, dietary fat is packaged into chylomicrons and transported through the lymphatic and blood systems, while the liver produces very-low-density lipoprotein particles that transport endogenously synthesised triglycerides. Lipoprotein lipase releases fatty acids from circulating triglyceride-rich particles so that tissues can use or store them. Triglycerides are therefore normal and necessary components of metabolism, but persistently elevated concentrations are associated with metabolic and cardiovascular abnormalities.
Triglyceride concentrations rise after eating because intestinal absorption temporarily increases the circulation of triglyceride-rich lipoproteins. The liver also synthesises triglycerides from fatty acids and excess carbohydrate and packages them into VLDL. Triglyceride-rich particles are progressively metabolised by lipoprotein lipase and related pathways, producing remnants and other particles. Efficient regulation depends on insulin action, liver metabolism, adipose-tissue storage and enzyme activity. When these processes are disrupted, triglycerides can accumulate in the bloodstream. Severe elevation can produce a risk of acute pancreatitis, while more moderate elevations are often considered in the context of overall cardiovascular and metabolic risk.
High Triglycerides can arise from obesity, insulin resistance, diabetes, excessive alcohol consumption, diets high in rapidly absorbed carbohydrates, hypothyroidism, kidney disease, liver disease and some medications. Genetic disorders can produce much more severe elevations through abnormalities in triglyceride-rich lipoprotein metabolism. Familial chylomicronaemia syndrome, for example, can cause extremely high triglycerides and recurrent pancreatitis because of severe impairment of triglyceride clearance. Secondary causes should be investigated when triglycerides are substantially elevated because correcting an underlying condition can significantly improve the lipid abnormality.
Triglycerides are not the same as cholesterol, although both are carried within lipoproteins and are routinely measured in lipid profiles. Cholesterol is a structural lipid and precursor for several important molecules, whereas triglycerides are principally used for energy storage and transport. Very-low-density lipoproteins and chylomicrons are particularly rich in triglycerides, while LDL is relatively cholesterol-rich. The two measurements can become correlated in metabolic disease, but a high triglyceride concentration does not automatically mean that LDL cholesterol is high. Comprehensive lipid interpretation therefore considers the full pattern rather than treating triglycerides as another name for cholesterol.
Laboratory assessment commonly occurs as part of a lipid profile. Triglycerides can vary substantially with recent food intake, alcohol exposure, illness and metabolic state, although non-fasting measurements are suitable for many routine assessments. When triglycerides are unexpectedly or markedly elevated, repeat or fasting testing may be appropriate. Extremely high results require particular attention because the risk of pancreatitis increases as concentrations become very high. Interpretation should also consider glucose control, thyroid function, kidney and liver health, medications and family history. The numerical value alone does not establish the cause of the abnormality.
Lifestyle management can substantially affect Triglycerides. Reducing excessive alcohol intake, improving glycaemic control, increasing physical activity and addressing excess adiposity where appropriate can lower concentrations. Dietary composition matters, particularly the amount of rapidly absorbed carbohydrate and total energy intake, while replacing some saturated fats with unsaturated fats can improve overall lipid profiles. For severe hypertriglyceridaemia, dietary fat restriction may become an important short-term medical intervention because chylomicron production contributes directly to triglyceride elevation. Advice should therefore be tailored to the degree and cause of elevation rather than applying one generic low-fat diet.
Medicines may be required when triglyceride elevation is severe or when overall cardiovascular risk warrants treatment of the broader lipid pattern. Statins primarily lower LDL cholesterol but can also reduce triglycerides to a variable extent and are important in many patients with combined lipid abnormalities because of their cardiovascular benefits. Fibrates, prescription omega-3-derived therapies and other treatments can be considered in specific circumstances. The distinction between therapies intended to reduce pancreatitis risk from very high triglycerides and those intended primarily to reduce cardiovascular events is clinically important. Not every supplement marketed for triglycerides has equivalent evidence or predictable potency.
A common misconception is that triglycerides are simply "fat in the blood" that can be interpreted without considering metabolism. They are carried in complex lipoprotein particles and participate in normal energy transport. Another misconception is that a normal triglyceride concentration guarantees cardiovascular health; a person can have normal triglycerides but elevated LDL cholesterol or other vascular risk factors. Conversely, elevated triglycerides can sometimes reflect a temporary post-meal or metabolic state rather than a fixed inherited disorder. Very high concentrations accompanied by severe upper abdominal pain, nausea or vomiting can indicate pancreatitis and require urgent assessment.
